Neogen Q4 Revenue Falls Short of Analyst Estimates

Neogen Corporation has reported Q4 revenue of $225.5 million, missing analyst expectations of $221.9 million. The company's adjusted EPS was $0.05, compared to the estimated $0.08. Neogen has also announced the launch of a molecular detection assay, Listeria Right Now, and the appointment of Mike Nassif as president and CEO. The company is also selling its cleaners and disinfectants business to Kersia SAS for $130 million.

Neogen Corporation (NEOG) reported its Q4 fiscal year 2025 earnings on July 29, 2025, with revenue of $225.5 million, falling short of analyst expectations of $221.9 million. The company's adjusted EPS was $0.05, compared to the estimated $0.08 [1].

Neogen's earnings report came with several significant announcements. The company launched Listeria Right Now, a molecular detection assay designed to detect Listeria species in the environment within two hours, without requiring enrichment. The product was unveiled at the International Association for Food Protection (IAFP) Annual Meeting in Cleveland, Ohio [3]. This new tool aims to enhance food safety by enabling faster, more informed sanitation decisions.

Additionally, Neogen appointed Mike Nassif as president and CEO, succeeding Dr. Jason Lilly. This move is part of the company's strategic focus on accelerating growth and innovation in the food safety and diagnostics markets [3].

In a separate transaction, Neogen sold its cleaners and disinfectants business to Kersia SAS for $130 million. This sale is expected to streamline Neogen's operations and allow the company to focus on its core competencies in food safety diagnostics and molecular detection technologies [3].

Despite the earnings miss, Neogen's stock price experienced a slight increase following the announcement. The company's focus on innovation and strategic changes may provide a positive outlook for investors, although the near-term impact on the stock price remains uncertain.

Investors should continue to monitor Neogen's earnings and future developments, as the company's strategic initiatives and new product launches could significantly impact its financial performance and stock price.

References:
[1] https://finance.yahoo.com/news/earnings-preview-neogen-neog-q4-140020560.html
[2] https://www.marketscreener.com/news/earnings-flash-neog-neogen-corporation-posts-fiscal-q4-adjusted-eps-0-05-per-share-vs-factset-e-ce7c5fd9df81f124
[3] https://www.neogen.com/ko/neocenter/press-releases/neogen-expands-pathogen-portfolio-new-rapid-test-listeria/